Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04304677
Other study ID # Algorithm20200211
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 22, 2016
Est. completion date October 1, 2022

Study information

Verified date October 2022
Source Samsung Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The presence of myocardial ischemia is the most important prognostic indicator in patients with coronary artery disease. Therefore, the purpose of percutaneous coronary intervention (PCI) is to relieve myocardial ischemia caused by the target stenosis. Fractional flow reserve (FFR) is an invasive physiologic index used to define functionally significant coronary stenosis, and its prognostic implications are supported by numerous studies. Contrary to the clear cutoff value and the benefit of FFR in pre-PCI evaluation, there have been various results regarding optimal cut-off values for post-PCI FFR. Nevertheless, the positive association between post-PCI FFR and the risk of future events has been reproduced by several studies. PCI with stent implantation is basically a local treatment and post-PCI FFR reflects both residual stenosis in the stented segment and remaining disease beyond the stented segment in the target vessel(s). Therefore, post-PCI FFR alone cannot fully discriminate the degree of contribution of each component. The relative increase of FFR with PCI is determined by the interaction of baseline severity of a target lesion, baseline disease burden of a target vessel, adequacy of PCI and residual disease burden in a target vessel. However, the most important problem in stratifying patients with better expected post-PCI physiologic results and following clinical outcome would be that there has been no clear method to identify these patients in pre-PCI phase. In this regard, we hypothesized that the amount of FFR step-up in pre-PCI pullback recording would determine the physiologic nature of target stenosis. For example, stenosis with sufficient step-up of FFR would deserve local treatment with PCI and these lesions would result in higher percent FFR increase, post-PCI FFR, and better clinical outcome than those without sufficient amount of FFR step-up. For this, we sought to develop automated algorithm to define physiologic major stenosis versus minor stenosis using pre-PCI pullback recording.


Description:

The current study cohort consisted with 3 cohort. In order to derive and validate the optimal cut-off values of FFR step-up amount for physiologic major vs minor stenosis and for physiologic minor stenosis vs. signal noise, the below 3 cohorts will be used. 1. Derivation cohort of defining the optimal cut off value of FFR step-up amount for physiologic major vs minor stenosis and for physiologic minor stenosis vs. signal noise. The cohort of no coronary atherosclerosis confirmed by both angiography and intravascular ultrasound will be derived from patients with heart transplantation (NCT02798731). The cohort of significant focal or diffuse obstructive coronary artery disease with functional significance defined by FFR<=0.80 will be derived from post-PCI registry of Samsung Medical Center. 2. Internal validation cohort will be post-PCI registry of Samsung Medical Center which enrolled 236 patients who underwent both pre- and post-PCI physiologic assessment after angiographically successful PCI using 2nd generation drug-eluting stent. Among this cohort, 234 patients with available pre-PCI pullback recording will be analyzed. 3. External validation cohort will be COE-PERSPECTIVE registry (NCT01873560) which enrolled patients who underwent PCI for lesions with FFR<=0.80 and underwent post-PCI physiologic assessment. Among the 835 patients, 252 patients with available pre-PCI pullback recording will be analyzed. For the association between physiologic major, minor, or mixed stenosis classified using the optimal cut-off values of FFR step-up amount for physiologic major vs minor stenosis and for physiologic minor stenosis vs. signal noise, the patient level pooled data of both Samsung Medical Center registry and COE-PERSPECTIVE registry will be used.


Recruitment information / eligibility

Status Completed
Enrollment 486
Est. completion date October 1, 2022
Est. primary completion date October 1, 2022
Accepts healthy volunteers No
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria: - any patient meets eligible criteria who underwent PCI with DES followed by invasive physiologic assessment at the index procedure - any patient who underwent PCI for lesions with pre-PCI FFR<=0.80 - available pre-PCI FFR pullback recording - available both post-PCI FFR measurement Exclusion Criteria: - unavailable pre-PCI FFR pullback recording - unavailable post-PCI FFR measurement - culprit vessel of acute coronary syndrome - failed achieving TIMI 3 flow at the end of PCI - left ventricular ejection fraction <30% - graft vessel - collateral feeder - in-stent restenosis - primary myocardial or valvular heart disease - in patient whose life expectancy less than 2 years - visible thrombus of target vessel segment

Study Design


Intervention

Device:
Percutaneous coronary intervention
Pre-PCI FFR pullback recording was done with conventional system Automated algorithm to calculate delta FFR per unit time was developed PCI was performed using 2nd generation DES

Locations

Country Name City State
Korea, Republic of Samsung Medical Center Seoul

Sponsors (6)

Lead Sponsor Collaborator
Samsung Medical Center Inje University Ilsan Paik Hospital, Keimyung University Dongsan Medical Center, Sejong General Hospital, Seoul National University Hospital, Ulsan University Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percent FFR increase after PCI ([Post-PCI FFR - Pre-PCI FFR]/Pre-PCI FFR * 100) Immediate post-PCI
Primary Post-PCI FFR FFR value measured after angiographically successful PCI Immediate post-PCI
Secondary Target Vessel Failure a composite of cardiac death, clinically-driven target vessel-related myocardial infarction, and clinically-driven target vessel revascularization. The target vessel will be defined as the treated vessel with 2nd generation DES which was assessed by post stent fractional flow reserve. 2 years after index procedure
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Active, not recruiting NCT04562805 - Infinity-Swedeheart Registry Based Randomized Clinical Trial (R-RCT) N/A
Recruiting NCT05292079 - CAPTURER PMCF Study ( rEPIC04D )
Recruiting NCT05292014 - ANGIOLITE PMCF Study ( rEPIC04F )
Recruiting NCT05292118 - Navitian PMCF Study ( rEPIC04C )
Recruiting NCT05292092 - Essential Pro PMCF Study ( rEPIC04E )
Completed NCT05292105 - NC Xperience PMCF Study( rEPIC04B)
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Not yet recruiting NCT04153383 - Milrinone on Cardiac Performance During Off-pump Coronary Artery Bypass Surgery
Recruiting NCT02729064 - Intraoperative Nasal Insulin Effect on Plasma and CSF Insulin Concentration and Blood Glucose Phase 1
Recruiting NCT02982434 - The New Pharmaceutical Composition Containing Botulinum Toxin to Treat Atrial Fibrillation Phase 2
Completed NCT02468401 - Prevention of Contrast Induced Nephropathy in Patients With Advanced Renal Dysfunction Undergoing Coronary Interventions N/A
Completed NCT02759406 - Evaluation of the Palmaz Mach-5 Grooved Bare Metal Coronary Stent System Versus the Palmaz Bare Metal Coronary Stent System in Patients With Symptomatic Ischemic Heart Disease: A Safety and Performance Study N/A
Recruiting NCT01681381 - Evaluate Safety And Effectiveness Of The Tivoli® DES and The Firebird2® DES For Treatment Coronary Revascularization N/A
Completed NCT01604213 - Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease Phase 4
Completed NCT01699802 - Influence of Inhaled Anaesthetics on Rebreathing of Carbon Dioxide When Using an Anaesthesia Gas Reflector (AnaConDa) N/A
Completed NCT01724567 - Copenhagen Study of Obese Patients With Ischemic Heart Disease Undergoing Low Energy Diet or Interval Training N/A
Completed NCT01334268 - RESOLUTE China RCT N/A
Completed NCT02159235 - Heavy Metals, Angiogenesis Factors and Osteopontin in Coronary Artery Disease (CAD) N/A